1. Home
  2. FLYX vs BOLD Comparison

FLYX vs BOLD Comparison

Compare FLYX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo flyExclusive Inc.

FLYX

flyExclusive Inc.

HOLD

Current Price

$0.88

Market Cap

63.1M

Sector

Finance

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

SELL

Current Price

$2.31

Market Cap

56.2M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
FLYX
BOLD
Founded
2015
2018
Country
United States
United States
Employees
N/A
28
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
63.1M
56.2M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
FLYX
BOLD
Price
$0.88
$2.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 180.6K
88.1K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
5.61
★ 32.47
EPS
★ N/A
N/A
Revenue
★ $375,877,000.00
N/A
Revenue This Year
$8.30
N/A
Revenue Next Year
$15.15
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 14.85
N/A
52 Week Low
$0.80
$0.96
52 Week High
$8.88
$3.16

Technical Indicators

Market Signals
Indicator
FLYX
BOLD
Relative Strength Index (RSI) 32.70 36.35
Support Level $0.80 $2.32
Resistance Level $1.27 $2.59
Average True Range (ATR) 0.11 0.09
MACD -0.02 -0.00
Stochastic Oscillator 16.81 14.93

Price Performance

Historical Comparison
FLYX
BOLD

About FLYX flyExclusive Inc.

flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: